Seaport Therapeutics, Inc.
SPTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002042347
No open-market purchases or sales by Seaport Therapeutics, Inc. insiders were filed in the last 90 days; 54 institutions reported holding it in 13F filings for Q2 2026, worth $815.3M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Seaport Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Seaport Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hombach Robert J. | Director | 13,000Indirect | Jun 24, 2026 | 2 |
| PureTech Health plc | 10% Owner | 16,685,013Indirect | May 6, 2026 | 1 |
| PureTech LYT, Inc. | 10% Owner | 16,685,013Indirect | May 6, 2026 | 1 |
| Crandell Keith | 10% Owner | 6,294,951Indirect | May 4, 2026 | 1 |
| Nelsen Robert | 10% Owner | 6,294,951Indirect | May 4, 2026 | 1 |
| Gillis Steven | 10% Owner | 6,294,951Indirect | May 4, 2026 | 1 |
| Burow Kristina | 10% Owner | 6,294,951Indirect | May 4, 2026 | 1 |
| ARCH Venture Fund XII, L.P. | 10% Owner | 6,294,951Indirect | May 4, 2026 | 1 |
| ARCH Venture Partners XII, LLC | 10% Owner | 6,294,951Indirect | May 4, 2026 | 1 |
| ARCH Venture Partners XII, L.P. | 10% Owner | 6,294,951Indirect | May 4, 2026 | 1 |
| Peterson Sandra E | Director | – | May 4, 2026 | 1 |
| Paul Steven M | Director | 863,031 | May 4, 2026 | 1 |
| Healy James | Director | 2,731,538Indirect | May 4, 2026 | 1 |
| Mates Sharon | Director | – | May 4, 2026 | 1 |
| Zohar Daphne | Chief Executive Officer | – | May 4, 2026 | 1 |
| Wheadon David E. | Director | – | May 4, 2026 | 1 |
| Loebel Antony | Chief Medical Officer | 20,109 | May 4, 2026 | 1 |
| Torres Denice | Director | 13,406Indirect | May 4, 2026 | 1 |
| White Lauren | Chief Financial Officer | 6,702Indirect | May 4, 2026 | 1 |
| Gladstein Lana | General Counsel | 33,515 | May 4, 2026 | 1 |
| Chen Michael Cunyuan | Chief Scientific Officer | 3,351 | May 4, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Hombach Robert J.Director | PPurchase | +13.0K | $18.14 | +$235.8K | New position13.0K after | |
| May 4, 2026 (view filing)6:02 PM ET | May 4 | Same day | Crandell Keith and 6 others10% Owner | PPurchase | +1.10M | $18.00 | +$19.8M | +21.2%6.29M after |